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Purpose of review
Pulmonary embolism is the most serious complication of venous thromboembolism, with
an elevated case/fatality rate. Patients who survived a first episode of pulmonary
embolism should be evaluated for the risk of recurrence and of chronic thromboembolic
pulmonary hypertension (CTEPH).
Recent findings
The risk of recurrence is higher in patients with unprovoked pulmonary embolism than in
those with transient risk factors. Persistent risk factors, such as active cancer and
antiphospholipid antibodies, are associated with high risk of recurrence. Recently,
elevated D-dimer levels after discontinuation of therapy have been identified as a risk
factor for recurrence. CTEPH is characterized by intravascular organization of emboli
and occurs in 0.5–1% of cases. Some patients with CTEPH have impaired fibrinolysis,
likely due to a structural abnormality of fibrin or fibrin clot. Echocardiography often
reveals signs of pulmonary hypertension. This should be confirmed by direct
measurement of pulmonary artery pressures at right heart catheterization.
Summary
CTEPH patients should receive life-long anticoagulation for preventing recurrent
pulmonary embolism. Pulmonary endarterectomy is the treatment of choice for patients
with proximal pulmonary vascular occlusion. Patients with predominantly distal
pulmonary vascular occlusion are candidates for pharmacological treatment. All patients
with unprovoked pulmonary embolism should be evaluated for long-term
anticoagulation.
Keywords
chronic thromboembolic pulmonary hypertension, D-dimer, fibrin, pulmonary embolism,
venous thromboembolism recurrence
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1070-5287Introduction
Venous thromboembolism (VTE) is a common disease,
with an incidence of about one in 1000 per year [1–3] and
with a progressive increase with increasing age. Deep
vein thrombosis (DVT) and pulmonary embolism are
generally considered to be two clinical manifestations
of the same disease. However, pulmonary embolism is
the most serious complication of VTE with an elevated
case/fatality rate. These patients have a risk of early death
from VTE, due to either the initial acute episode or
recurrent VTE, which is substantially higher for patients
with pulmonary embolism than for those with DVT only.
If a patient survives a first acute episode of pulmonary
embolism and adequate anticoagulant treatment is
started, two major problems arise: the risk of recurrence
when anticoagulation is stopped and the risk of develop-1070-5287  2011 Wolters Kluwer Health | Lippincott Williams & Wilkinsing chronic thromboembolic pulmonary hypertension
(CTEPH).Risk of recurrence of venous
thromboembolism
Several trials [4–6] and observational studies [7,8]
indicate that the risk of recurrent VTE after stopping
anticoagulant therapy was much lower if VTE had been
provoked by a reversible risk factor, such as surgery,
rather than if the episode of VTE was unprovoked
[7,9]. Reversible provoking risk factors include major
and minor conditions. Major factors are surgery,
hospitalization, or plaster cast immobilization, all within
1 month, and pregnancy. Other conditions, such as oral
contraceptive treatment, traveling over long distances,
or major risk factors occurring between 1 and 3 months
before the diagnosis of VTE are considered minor riskDOI:10.1097/MCP.0b013e328349289a
Incidence of recurrent pulmonary embolism Poli and Miniati 393
Key points
 The risk of recurrent pulmonary embolism was 3.1-
fold higher in patients presenting with pulmonary
embolism than in patients with proximal deep
vein thrombosis.
 Abnormal D-dimer levels at 1 month after anti-
coagulant treatment withdrawal was an independent
risk factor for recurrent venous thromboembolism.
 Several prospective studies report an incidence of
chronic thromboembolic pulmonary hypertension
(CTEPH) ranging from 0.6 to 1.3%.
 Fibrin resistance to lysis occurs in patients with
CTEPH.
 Pulmonary endarterectomy is the treatment of
choice for CTEPH.factors. Their role in determining an acute VTE event is
still debated. The risk of recurrent VTE after stopping
oral anticoagulant treatment (OAT) in patients with a first
episode of VTE associated with a major transient risk
factor is about 3% per year [3,10]. By contrast, patients
with unprovoked VTE have a high risk for recurrent
VTE, estimated as 17.5% in the first 2 years with a
persistent increase for many years [7]. In a patient-level
meta-analysis of seven prospective studies in patients
with a first VTE followed after anticoagulation with-
drawal, the 5-year cumulative rate of recurrent VTE in
patients with pulmonary embolism was 22.0% for any
recurrence (DVT or pulmonary embolism) and 10.6% for
pulmonary embolism recurrence. The risk of recurrent
pulmonary embolism was 3.1-fold higher in patients
presenting with pulmonary embolism than in patients
with proximal DVT [hazard ratio 3.1; 95% confidence
interval (CI) 1.9–5.1] [11].Factors affecting recurrence
The association between malignancy and VTE is well
established, and cancer patients with venous thromboem-
bolism are more likely to develop recurrent VTE than
those without [12]. The elevated risk of VTE recurrence
in patients with malignancy leads to the recommendation
to prolong anticoagulant therapy indefinitely or until the
cancer is resolved [13].
Evidence from prospective studies [14,15] suggests that
the presence of hereditary thrombophilia is not a critical
determinant of the risk of recurrence. The recurrence
risk is increased only in patients who have at least two
abnormalities. Patients should be evaluated also for
the identification of acquired thrombophilia. The anti-
phospholipid antibodies syndrome is diagnosed when a
patient who suffered from a thrombotic event presents
positivity for lupus anticoagulant and/or antiphospholipid
antibodies against cardiolipin or b(2)-glycoprotein I (con-
firmed in at least two blood samples 12 weeks apart).
These patients carry an elevated risk of recurrence and,
therefore, need life-long anticoagulant treatment with
vitamin K antagonists (VKAs) [International Normalized
Ratio (INR) 2.0–3.0] [16].
Sex is also a determinant of the risk of recurrent VTE.
In patients with a first unprovoked VTE, men have a
2.2-fold higher risk of recurrence than women. The risk
of recurrence remained 1.8-fold higher in men than in
women, even after adjustment for women with initial
hormone-associated events [17].
Recently, it has been demonstrated that clotting
activation, detected after withdrawal of anticoagulant
therapy, is associated with recurrence. Palareti et al.
[18] observed that elevated D-dimer levels, measured1 month after stopping warfarin in patients who undergo
a standard period of anticoagulation after a first episode of
VTE, were associated with an increased risk of recurrent
VTE. This observation was confirmed by several studies
[19]. Overall, it was confirmed that in patients who have
completed at least 3 months of anticoagulation after a first
episode of unprovoked VTE, a negative D-dimer result
measured 1 month after anticoagulation withdrawal is
associated with a 3.5% annual risk of recurrent disease,
whereas a positive D-dimer result is associated with an
8.9% annual risk of recurrence. In particular, in a group of
patients with pulmonary embolism as the index event,
the finding of abnormal D-dimer levels at 1 month after
anticoagulant treatment withdrawal was an independent
risk factor for recurrent VTE [20]. In this study, the rate
of recurrence was 11.3 per 100 patient-years in patients
with elevated D-dimer levels and 2.6 per 100 patient-
years in those with normal D-dimer levels. Management
studies are now underway to assess the value of D-dimer
test in predicting VTE recurrence in clinical practice
(DULCIS Study, D-dimer and ULtrasonography in
Combination Italian Study; ClinicalTrials.gov identifier:
NCT00954395).Oral anticoagulant treatment
Patients presenting with pulmonary embolism have a
higher incidence of fatal recurrent VTE than those
with isolated DVT. Therefore, defining the duration
of anticoagulant treatment is particularly important for
patients suffering from pulmonary embolism. The effi-
cacy of oral anticoagulants in preventing recurrent VTE
is well known. Data from the literature indicate that
indefinite treatment with conventional-intensity VKA
(target INR 2.5) reduces recurrent VTE by approxi-
mately 90% [21,22]. However, the treatment is associated
with a significant risk of major bleeding. In specialized
anticoagulation services, this risk ranges from 0.32 to
2.1% per year, with the risk of fatal bleeding ranging
394 Disorders of the pulmonary circulationfrom 0 to 0.25% per year [23]. A significant clinical impact
of bleeding in patients anticoagulated for VTE has been
demonstrated in a recent meta-analysis, which reported
a case-fatality rate of major bleeding of 13.4% [95%
confidence interval (CI) 9.4–17.4], with a rate of intra-
cranial hemorrhage of 1.15% per 100 patient-years (95%
CI 1.14–1.16) [24].
There has been only one evaluation of the duration of
VKA therapy in a large sample of patients with proven
pulmonary embolism [25]. After 3 months of successful
anticoagulation, patients were randomly assigned to
discontinue therapy immediately or extend therapy to
6 months or 1 year. Extending the duration of treatment
beyond 3 months did not reduce the recurrence rates.
Recently, the American College of Chest Physicians
recommended that patients with unprovoked VTE
should receive at least 3 months of anticoagulation and
should then be evaluated for the risk–benefit ratio of
long-term therapy [13]. Long-term treatment is recom-
mended in the patients in whom risk factors for bleeding
are absent and in whom a good anticoagulant monitoring
is achievable. However, the decision about treatment is
ultimately left to the attending physician, who should
assess the risk–benefit ratio in an individual case,
and to patient willingness to prolong treatment. The
results of ongoing management strategies, based on
D-dimer levels, measured after stopping a standard
period of anticoagulant therapy, will probably offer the
clinicians a valid support for decision making.Chronic thromboembolic pulmonary
hypertension
CTEPH is a rare complication of pulmonary embolism
that is associated with severe morbidity and high
mortality [26]. In the United States, an incidence of
0.1–0.5% was estimated, based on the number of cases
diagnosed as having CTEPH and the annual rate of
patients surviving an acute embolic event [27,28]. This
low incidence rate has been questioned, and the actual
incidence of CTEPH is still a matter of controversy.
In a small prospective study comprising 78 cases of
pulmonary embolism, CTEPH was diagnosed in three
(8.8%) of the 34 patients who had a pulmonary artery
systolic pressure (PASP) higher than 30 mmHg as esti-
mated by Doppler echocardiography at 1 year of diag-
nosis [29]. However, the data set is incomplete, with 39%
of the eligible patients not included in the study and 14%
lost to follow-up [29]. Pengo et al. [30] found a cumulative
incidence rate of 1% at 6 months, 3.1% at 1 year, and 3.8%
at 2 years, with no subsequent increase in incidence. In
that study, the investigation for CTEPH was prompted
by the occurrence of unexplained exertional dyspnea.However, no lung scan follow-up was pursued to evaluate
the restoration of pulmonary perfusion, which would have
allowed them to identify previous unrecognized episodes
of pulmonary embolism.
Several broad prospective studies, published between
2006 and 2010, were in agreement in reporting an
incidence of CTEPH in the range of 0.6–1.3% [31,32,
33,34], which is probably the real incidence of the
disease.
Pathophysiology
CTEPH is characterized by intravascular organization of
emboli that may yield a complete fibrotic obliteration of
the vascular lumen. If obliteration is extensive, it brings
about an increase in pulmonary vascular resistance (PVR),
which, in turn, determines sustained pulmonary arterial
hypertension. Notably, pulmonary vascular lesions, very
similar to those of idiopathic pulmonary hypertension, are
found in the pulmonary vessels free of embolic material
[35]. Such widespread arteriopathy contributes to the
elevation of the pulmonary artery pressure [36].
The pathogenesis of CTEPH is still largely unknown.
The prevalence of hereditary thrombophilia (deficiencies
of antithrombin, protein C or protein S, or factor II and
V mutations) is not significantly higher in CTEPH as
compared with idiopathic pulmonary hypertension, or
healthy individuals [36]. Antiphospholipid antibodies
are detected in 21% of the patients [36] and elevated
levels of factor VIII were found in 41% of the patients
with CTEPH [37].
In 2006, Morris et al. [38] first reported that fibrin isolated
from 10 patients with CTEPH is resistant to plasmin-
mediated lysis, as compared with controls. In particular,
cleavage of the amino terminus of the b chain was
significantly slower in CTEPH than in controls. It was
hypothesized that persistence of the amino terminus
residues within the pulmonary vessels could promote
the organization of thromboemboli into chronic intra-
vascular scars, thereby determining sustained elevation
of PVR [38].
Recently, we confirmed that fibrin resistance to lysis
uniformly occurs in patients with established CTEPH
[39]. Such abnormality was also found in idiopathic and
in some forms of acquired pulmonary hypertension [39].
In pulmonary hypertensive patients, the resistance of
fibrin to lysis was observed shortly after the incubation
with plasmin. This suggests a structural abnormality of
the fibrin molecule itself, or a modification in the overall
architecture of the fibrin clot that makes it resistant to
lysis. The above data may be relevant to the pathogenesis
of pulmonary hypertension, as it is recognized that pro-
longed exposure to fibrin or fibrin fragments stimulates
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cells, fibroblasts and pulmonary arterial smooth muscle
cells, thereby suggesting a potential role in vascular
remodeling and angiogenesis [40,41].
Clinical presentation and diagnosis
The clinical presentation of CTEPH is nonspecific,
featuring progressive dyspnea on exertion, palpitations,
hemoptysis, syncope, and, when right heart failure
occurs, dilated neck veins and ankle edema. Usually,
there is a clinically ‘silent’ period that may last from a few
months to many years, as the acute embolic event.
However, a substantial proportion of the patients with
proven CTEPH have no known history of pulmonary
embolism [42]. In fact, pulmonary embolism is still
a largely underdiagnosed clinical entity [2].
Simple laboratory tests, such as electrocardiogram
and chest radiograph, are helpful in strengthening the
suspicion of CTEPH [26]. Electrocardiographic signs
of right ventricular overload, although nonspecific, may
prompt further investigation by transthoracic echocardio-
graphy. Chest radiographic abnormalities in chronic
pulmonary embolism were first described some 50 years
ago [43]. They include dilatation on the pulmonary
artery trunk (Fleischner sign) and of the hilar arteries
with abrupt tapering of the distal arteries. Increased
translucency, due to focal oligoemia of the lung, usually
coexists. Dilatation of the right ventricle is best recog-
nized by the increased area of contact between the heart
and the anterior chest wall in the lateral roentgenogram
[43].
Perfusion or ventilation–perfusion scintigraphy is an
important step in the diagnostic work-up of CTEPH
[43,44]. Multiple segmental or lobar perfusion defects with
preserved ventilation are strongly suggestive of chronic
pulmonary embolism, particularly when they remain un-
changed in sequential lung scans. Such finding mandates
further objective testing for suspected CTEPH.
In clinical practice, pulmonary hypertension is often
found, unexpectedly, on transthoracic Doppler echocar-
diography requested for another indication. Even though
echocardiography is very useful in the evaluation of
suspected CTEPH, it should be considered that Doppler
echocardiography estimates of PASP are often inaccurate
[45,46] due to a poor visualization of the tricuspid
regurgitation jet, or to an unreliable estimation of the
right atrial pressure from the compressibility of the
inferior vena cava [46,47].
Therefore, physicians should not be overly reliant on
such estimates in their approach to patients with suspec-
ted CTEPH, or in assessing changes in PASP in response
to therapy.The definitive confirmation or exclusion of CTEPH rests
on the direct measurement of pulmonary artery pressures
at right heart catheterization. Hemodynamic criteria to
establish a diagnosis of precapillary pulmonary hyper-
tension include a mean pulmonary arterial pressure of
more than 25 mmHg at rest with a pulmonary occlusion
pressure of 15 mmHg or less and a normal or reduced
cardiac output [48]. Hemodynamic assessment should
also include the vasoreactivity test with inhaled nitric
oxide to identify the patients who retain some degree of
active pulmonary vasodilation [48]. In a recent study, a
decrease in the mean pulmonary arterial pressure higher
than 10.4%, with inhaled nitric oxide, was found to be a
strong predictor of long-term survival and freedom from
lung transplantation in patients with CTEPH undergoing
pulmonary endarterectomy (PEA) [49].
Treatment
Even though patients with CTEPH should receive life-
long anticoagulation for preventing recurrent pulmonary
embolism, such treatment cannot in itself halt the disease
progression. PEA is regarded as the treatment of choice
for CTEPH patients with proximal pulmonary vascular
occlusion [48]. When considering the option of PEA,
it is necessary to visualize the location and the extent
of pulmonary intraluminal occlusion. In this regard,
selective or superselective pulmonary angiography is
the modality of choice [48]. Multidetector computed
tomography angiography is becoming a valid alternative
to selective angiograms, as it provides a detailed three-
dimensional reconstruction of the pulmonary vascular tree.
PEA is contraindicated in the patients with pre-
dominantly distal pulmonary vascular occlusion and in
those with severe comorbidities associated with an
increased risk of perioperative mortality (particularly,
chronic obstructive or restrictive lung diseases).
Such patients, and those with persistent pulmonary hy-
pertension after PEA, are candidates for pharmacological
treatment [48]. As of now, only one randomized clinical
trial has been conducted in patients with inoperable
CTEPH [50]. In that study, a 16-week oral therapy with
bosentan (a dual endothelin receptor antagonist) resulted
in a significant reduction of PVR and NT-proBNP levels
as compared with the placebo group [50]. It is, however,
unknown whether pharmacotherapy is capable of impro-
ving survival in the patients with inoperable CTEPH and
in those who have persistent elevation of the mean
pulmonary arterial pressure after PEA.Conclusion
Patients who survive a first episode of pulmonary embo-
lism should be evaluated for the occurrence of CTEPH
and to define optimal duration of anticoagulant treatment
396 Disorders of the pulmonary circulationto prevent recurrence, balancing the risk–benefit ratio
of therapy. In particular, patients with an unprovoked
pulmonary embolism should be carefully evaluated for
long-term treatment.Acknowledgement
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